Last reviewed · How we verify
Training+Simvastatin+Q10
Training+Simvastatin+Q10 is a Combination therapy (statin + supplement + lifestyle intervention) Small molecule drug developed by University of Copenhagen. It is currently FDA-approved for Cardiovascular risk reduction in patients with dyslipidemia or statin-treated populations. Also known as: Simvastatin KRKA, SQ.
This combination therapy uses exercise training with simvastatin (a statin) and coenzyme Q10 (CoQ10) to reduce cardiovascular risk through lipid lowering and mitochondrial support.
The "Living With Statins - Interventional Exercise Study" (LIFESTAT) investigated the effects of training combined with simvastatin and coenzyme Q10 on cardiovascular disease and diabetes mellitus. Simvastatin is a small molecule that lowers cholesterol levels, and its mechanism of action is not specified in the provided information.
At a glance
| Generic name | Training+Simvastatin+Q10 |
|---|---|
| Also known as | Simvastatin KRKA, SQ |
| Sponsor | University of Copenhagen |
| Drug class | Combination therapy (statin + supplement + lifestyle intervention) |
| Target | HMG-CoA reductase (simvastatin); mitochondrial electron transport chain (CoQ10) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Simvastatin inhibits HMG-CoA reductase to lower LDL cholesterol and reduce atherosclerotic cardiovascular disease risk. CoQ10 supplementation counteracts statin-induced depletion of this essential mitochondrial cofactor, potentially improving muscle function and energy metabolism. Exercise training enhances cardiovascular fitness and metabolic health synergistically with pharmacotherapy.
Approved indications
- Cardiovascular risk reduction in patients with dyslipidemia or statin-treated populations
Common side effects
- Muscle pain or myalgia (simvastatin)
- Elevated liver enzymes (simvastatin)
- Gastrointestinal upset
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Training+Simvastatin+Q10 CI brief — competitive landscape report
- Training+Simvastatin+Q10 updates RSS · CI watch RSS
- University of Copenhagen portfolio CI
Frequently asked questions about Training+Simvastatin+Q10
What is Training+Simvastatin+Q10?
How does Training+Simvastatin+Q10 work?
What is Training+Simvastatin+Q10 used for?
Who makes Training+Simvastatin+Q10?
Is Training+Simvastatin+Q10 also known as anything else?
What drug class is Training+Simvastatin+Q10 in?
What development phase is Training+Simvastatin+Q10 in?
What are the side effects of Training+Simvastatin+Q10?
What does Training+Simvastatin+Q10 target?
Related
- Drug class: All Combination therapy (statin + supplement + lifestyle intervention) drugs
- Target: All drugs targeting HMG-CoA reductase (simvastatin); mitochondrial electron transport chain (CoQ10)
- Manufacturer: University of Copenhagen — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Cardiovascular risk reduction in patients with dyslipidemia or statin-treated populations
- Also known as: Simvastatin KRKA, SQ
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing